PIK3CA
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
As of the edition of 20 October 2026, PIK3CA (phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, UniProt P42336) has 46 drugs tested at it and 41 companies on the list, 19 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P42336
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 139
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Immune system; Urinary and reproductive; Nervous system; Pregnancy and women's health; Inherited and neonatal
- Registered trials of its drugs
- 523
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 12 |
| Went quiet | 14 |
| Stopped | 13 |
| Status not established | 3 |
| Total | 46 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Alpelisib | Marketed | Phase 4 | Ends 2033 |
| Buparlisib | Stopped | Phase 3 | none listed |
| Copanlisib | Marketed | Phase 3 | Ends 2032 |
| Inavolisib | Marketed | Phase 3 | Ends 2038 |
| Dactolisib | Went quiet | Phase 3 | none listed |
| Gedatolisib | Marketed | Phase 3 | Ends 2031 |
| Samotolisib | Stopped | Phase 2 | none listed |
| Pictilisib | Went quiet | Phase 2 | none listed |
| Taselisib | Stopped | Phase 3 | none listed |
| Paxalisib | Active | Phase 3 | none listed |
| Pilaralisib | Went quiet | Phase 2 | none listed |
| Serabelisib | Active | Phase 2 | none listed |
12 of 46 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 19 |
| Route B | 4 |
| Engaged | 15 |
| Undetermined | 3 |
| Total on the list | 41 |
The other 38 companies at PIK3CA
In the product41 companies in all; 38 are not named here, and no score is.
See the 41 companies at PIK3CA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.